Collegium Q2 Revenue Tops $200M, but Nucynta Pricing Pressure Forces Full-Year Guidance Cut

summarizeSummary

Collegium reported Q2 2026 revenue of $199.9 million, up 6% year-over-year, but lowered full-year guidance due to weaker Nucynta pricing. ADHD portfolio strength, including a partial quarter of AZSTARYS sales, was offset by a 9% decline in pain portfolio revenues.

check_boxKey Events · Earnings and Guidance · COLL

• Q2 Revenue Beats, But GAAP Net Loss

  Product revenues, net were $199.9 million, up 6% year-over-year, driven by JORNAY PM ($46.1M, +41%) and a partial quarter of AZSTARYS ($12.9M). GAAP net loss was ($15.1) million, or ($0.46) per share, due to $62.9 million in intangible amortization and $24.1 million in acquisition-related expenses.

• Full-Year Guidance Cut on Nucynta Weakness

  Collegium lowered its 2026 product revenue guidance to $825-$855 million (from $865-$895M) and adjusted EBITDA to $445-$470 million (from $475-$500M), citing lower-than-expected net pricing on authorized generic versions of Nucynta. AZSTARYS revenue guidance was raised to $65-$75 million.

• ADHD Portfolio Momentum Offsets Pain Decline

  JORNAY PM prescriptions grew 13.1% year-over-year, with prescribers reaching an all-time high of over 30,000. AZSTARYS contributed $12.9 million in its first partial quarter. Pain portfolio revenues fell 9% to $140.9 million, with Nucynta franchise down 24% to $35.2 million.

• Strong Cash Flow and Manageable Leverage

  The company generated $71.3 million in cash from operations in Q2, ending with $129.5 million in cash and equivalents. Net debt to adjusted EBITDA was 2.1x as of June 30, 2026, providing flexibility for debt repayment and share repurchases.

auto_awesomeAnalysis · COLL · Life Sciences

Collegium delivered a mixed quarter: record ADHD revenue driven by JORNAY PM's 41% surge and the first contribution from the newly acquired AZSTARYS, but the pain portfolio is eroding faster than expected, forcing a $40 million cut to the full-year product revenue midpoint and a $30 million cut to adjusted EBITDA. The GAAP net loss of $15.1 million reflects heavy acquisition-related amortization and integration costs, while adjusted EBITDA of $113.8 million shows the underlying business remains highly cash-generative. The updated guidance signals that Nucynta's authorized generic pricing is deteriorating more than management anticipated, offsetting the ADHD strength. With $129.5 million in cash and 2.1x net leverage, the balance sheet can absorb the revision, but the lowered outlook raises questions about the durability of the legacy pain franchise just as the company is integrating a major acquisition.